LRRK2 靶点蛋白|抗体药物|临床药物信息

LRRK2信息

英文名称：Leucine-rich repeat serine/threonine-protein kinase 2
中文名称：富含亮氨酸重复的丝氨酸/苏氨酸蛋白激酶-2
靶点别称：PARK8，LRRK2，Leucine Rich Repeat Kinase 2，Leucine-Rich Repeat Serine/Threonine-Protein Kinase 2，Parkinson Disease (Autosomal Dominant) 8，Augmented In Rheumatoid Arthritis 17，Dardarin，AURA17，RIPK7，ROCO2，Leucine-Rich Repeat Serine-Threonine Protein Kinase-2，DKFZp434H2111，FLJ45829

上市药物数量：0
临床药物数量：5
最高研发阶段：临床三期

LRRK2产品列表

筛选结果

产品库

在研 (2)

物种

Human (2)

标签

His Tag (2)

属性

Protein (2)

标记

Unconjugated (2)

货号	物种	产品描述	蛋白结构	纯度	活性
LK2-H5243	Human	Human LRRK2 Protein, His Tag
LK2-H5245	Human	Human LRRK2 (G2019S) Protein, His Tag

LAMP5 分子别名

LAMP5 分子背景

LAMPs (lysosome associated membrane proteins) represent a family of glycosylated proteins present predominantly on the membrane of lysosomes whose expression can vary among different tissues, suggesting a separation of functions. LAMP5 is expressed highly and specifically in MLL-r leukemia. LAMP5 is a direct target of the oncogenic MLL-fusion protein. LAMP5 depletion significantly inhibited leukemia cell growth in vitro and in vivo. Functional studies showed that LAMP-5 is a novel modulator of innateimmune pathways in MLL-r leukemias. Downregulation of LAMP5 led to inhibition of NF-κB signaling and increased activation of type-1 interferon signaling downstream of Toll-like Receptor/Interleukin 1 Receptor activation.

LAMP5 前沿进展

LRRK2临床药物信息

英文名称	研发代码	研发阶段	公司	适应症	临床试验
NEU-723	NEU-723	临床一期		帕金森病	详情
VRN-01	VRN-01	临床一期	Voronoi	胰腺癌, 乳腺癌	详情
WXWH0226	WXWH0226; WXWH-0226	临床一期	贵州伊诺其尼科技有限公司, 无锡药明康德新药开发股份有限公司	帕金森病	详情
BIIB-094	BIIB-094; ION-859; IONIS-BIIB7Rx	临床二期	百健	帕金森病	详情
DNL-151	BIIB-122; DNL-151	临床三期	罗氏, 百健	帕金森病	详情

会议日历

会议一览

LRRK2